2183.T Живые сигналы | Максимизируйте прибыль с Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 апр. 2024 @ 09:15):

Linical Co., Ltd. provides drug development services primarily in the areas of oncology and central nervous system to pharmaceutical companies worldwide...

Stats
Объем за сегодня	139 500
Средний объем	104 790
Рыночная капитализация	8.94B
EPS	¥0 ( 2024-02-13 )
Дата следующего отчета о доходах	( ¥0 ) 2024-05-12
Last Dividend	¥14.00 ( 2023-03-30 )
Next Dividend	¥0 ( N/A )
P/E	13.14
ATR14	¥0.529 (0.13%)

Объем Корреляция

Длинно: -0.32 (neutral)

Кратко: -0.93 (very strong negative)

Signal:(12.141) Possible Trading Opportunity Present (swing)

Linical Co., Ltd. Корреляция

10 Самые положительные корреляции

10 Самые отрицательные корреляции

Вы знали?

Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).

Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.

Linical Co., Ltd. Корреляция - Валюта/Сырье

0.60
( weak )

0.40
( neutral )

0.47
( neutral )

0.41
( neutral )

-0.37
( neutral )

-0.57
( weak negative )

Linical Co., Ltd. Финансовые показатели

Annual	2022
Выручка:	¥12.52B
Валовая прибыль:	¥4.16B (33.25 %)
EPS:	¥44.47

FY	2022
Выручка:	¥12.52B
Валовая прибыль:	¥4.16B (33.25 %)
EPS:	¥44.47

FY	2022
Выручка:	¥11.56B
Валовая прибыль:	¥3.61B (31.26 %)
EPS:	¥35.00

FY	2021
Выручка:	¥10.28B
Валовая прибыль:	¥2.77B (26.92 %)
EPS:	¥23.91

Financial Reports:

No articles found.

Linical Co., Ltd. Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
¥0 (N/A)	¥0 (N/A)	¥14.00 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)

Linical Co., Ltd. Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 3.07 - Decrease likely (38.54%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	¥3.00	2009-03-26
Last Dividend	¥14.00	2023-03-30
Next Dividend	¥0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	16	--
Total Paid Out	¥111.75	--
Avg. Dividend % Per Year	0.00%	--
Score	2.78	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	3.07
Div. Directional Score	7.05	--

Next Divdend (Est)
(2024-12-31)

¥0 Estimate 0.00 %

Dividend Stability

0.05 Very Bad

Dividend Score

2.78

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for JPX

Symbol	Title	Last dividend	Frequency	Yearly Dividend
8136.T	Ex Dividend Junior	2023-09-28	Annually	0.00%
7483.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
6707.T	Ex Dividend Knight	2023-09-28	Annually	0.00%
6058.T	Ex Dividend Junior	2024-02-28	Sporadic	0.00%
4733.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
3981.T	Ex Dividend Junior	2023-12-28	Annually	0.00%
3186.T	Ex Dividend Junior	2023-11-29	Annually	0.00%
2180.T	Ex Dividend Junior	2023-12-28	Annually	0.00%
9052.T	Ex Dividend Junior	2023-09-28	Annually	0.00%
7942.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0543	1.500	8.91	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0385	1.200	8.72	10.00	[0 - 0.3]
returnOnEquityTTM	0.0876	1.500	-0.138	-0.206	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	1.712	0.800	6.44	5.15	[1 - 3]
quickRatioTTM	1.467	0.800	6.08	4.86	[0.8 - 2.5]
cashRatioTTM	1.018	1.500	5.46	8.19	[0.2 - 2]
debtRatioTTM	0.154	-1.500	7.43	-10.00	[0 - 0.6]
interestCoverageTTM	71.54	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	44.92	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	44.92	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0.349	-1.500	8.60	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.324	1.000	7.93	7.93	[0.2 - 0.8]
operatingProfitMarginTTM	0.0925	1.000	-0.151	-0.151	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.372	1.000	9.05	9.05	[0.2 - 2]
assetTurnoverTTM	0.708	0.800	8.61	6.89	[0.5 - 2]
Total Score				11.04

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	13.15	1.000	8.77	0	[1 - 100]
returnOnEquityTTM	0.0876	2.50	-0.0884	-0.206	[0.1 - 1.5]
freeCashFlowPerShareTTM	44.92	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	3.79	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	44.92	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-0.235	1.500	-4.90	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0810	1.000	-0.474	0	[0.1 - 0.5]
Total Score				3.07

Linical Co., Ltd.

Linical Co., Ltd. provides drug development services primarily in the areas of oncology and central nervous system to pharmaceutical companies worldwide. The company offers drug development consulting services, such as market analysis of products in development, regulatory affairs consultation support, and licensing support. It also provides clinical research and development, and contract medical affairs services, including front-end services comprising project management, monitoring, quality control, vendor management, auditing, and clinical research secretariat; and back-end services, which include data management, bio statistical analysis, medical writing, pharmacovigilance, and medical management. The company was incorporated in 2005 and is headquartered in Osaka, Japan.